Combined Shoulder Anterior Capsule and Suprascapular Nerve Block Versus Interscalene Block in Shoulder Surgery

NCT06519851 | Not Yet Recruiting

• 1 other identifier: SHAC & SSNB
• Study Type: interventional
• Target: 42
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study aims to evaluate the postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) versus Interscalene block (ISB) during the first 24 hours following shoulder surgery.

Conditions

Shoulder Pain

Outcome Measures

Primary Outcomes (1)

• Evaluation of postoperative analgesia measured by Visual analogue scale during the first 24 hours after shoulder surgery.

  Visual analogue scale consists of a 10 centimeter line, with two end points representing 0 (no pain) and 10 (worst imaginable pain)

  Pain will be assessed at 1st hour, then at 2, 6, 12, 18 and 24 hours postoperatively using VAS score.

Secondary Outcomes (2)

• The first time to rescue opioid analgesia, and the total opioid consumption in the first 24 hours postoperatively

  24 hours postoperatively

• Any Complications related to the blocks

  24 hours postoperatively

Study Arms (2)

• SSNB & SHAC

ACTIVE COMPARATOR

patients will receive general anesthesia + ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)

Other: suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%

• Interscalene

PLACEBO COMPARATOR

patients will receive general anesthesia + ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus.

Other: Interscalene block with 20 ml bupivacaine 0.25%

Interventions

suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25% OTHER

postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)

• SSNB & SHAC

Interscalene block with 20 ml bupivacaine 0.25% OTHER

postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus

• Interscalene

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients of both genders
• patients aged 18-65 years
• BMI of less than 30
• American Society of Anesthesiologists (ASA) physical status I-II,
• Patients scheduled for unilateral shoulder surgery under general anesthesia.

You may not qualify if:

• Patient refusal
• BMI of 30 or more
• ASA III or more
• Pregnancy or breast feeding
• Uncooperative patients with communication difficulties, which might prevent a reliable postoperative assessment.
• Shoulder revision surgery
• Pre-existing neurological deficits or neuropathy
• Known contraindications to peripheral nerve block, including local skin infections in the block procedure area, bleeding diathesis, coagulopathy
• Patients with chest problems not eligible for ISB

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Shoulder Pain

Interventions

Bupivacaine; Dental Occlusion

Condition Hierarchy (Ancestors)

Arthralgia; Joint Diseases; Musculoskeletal Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines; Dentistry; Dental Physiological Phenomena; Digestive System and Oral Physiological Phenomena

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assisstant lecturer

Study Record Dates

• First Submitted: July 6, 2024
• First Posted: July 25, 2024
• Study Start: August 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: December 1, 2025
• Last Updated: August 6, 2024

Record last verified: 2024-08